High-density lipoprotein cholesterol and left venticular mass index in peritoneal dialysis

Peritoneal Dialysis International

Volumn 28, Issue 6, 2008, Pages 611-616

  Ikee, Ryota ^a   Hamasaki, Yoshifumi ^a   Oka, Machiko ^a   Maesato, Kyoko ^a   Mano, Tsutomu ^a   Moriya, Hidekazu ^a   Ohtake, Takayasu ^a   Kobayashi, Shuzo ^a  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

Cardiovascular disease; Dyslipidemia; High density lipoprotein cholesterol; Hypervolemia; Left ventricular hypertrophy; Left ventricular mass index; Lipid profile; Residual renal function

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATRIAL NATRIURETIC FACTOR; C REACTIVE PROTEIN; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS; URIC ACID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; BLOOD; ECHOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; SODIUM INTAKE;

AGED; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; SODIUM, DIETARY;

EID: 60249094307     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802800611     Document Type: Article

References (38)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-69.
2. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in endstage renal disease. Kidney Int 1989; 36:286-90.
3. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: 1277-85.
4. Levin A, Thompson CR, Ethier J, Carlisle JF, Tobe S, Mendelssohn D, et al. Left ventricular mass index in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34:125-34.
5. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46:320-7.
6. Ohashi H, Oda H, Ohno M, Sakata S. Predictors of survival in continuous ambulatory peritoneal dialysis patients: the importance of left ventricular hypertrophy and diabetic nephropathy. Adv Perit Dial 1999; 15:87-90.
7. Silaruks S, Sirivongs D, Chunlertrith D. Left ventricular hypertrophy and clinical outcome in CAPD patients. Perit Dial Int 2000; 20:461-6.
8. Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cytrupi S, et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than hemodialysis patients. Nephrol Dial Transplant 2001; 16:1459-64.
9. Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant 2002; 17:1661-6.
10. Wang AY, Wang M, Woo J, Law MC, Chow KM, Li PK, et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62:639-47.
11. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14(9 Suppl 4):S315-20.
12. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26:523-39.
13. Sundstrom J, Lind L, Vessby B, Andren B, Aro A, Lithell HO. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation 2001; 103: 836-41.
14. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25:359-64.
15. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55:613-18.
16. Ferrara LA, Vaccaro O, Cardoi O, Laurenzi M, Mancini M, Zanchetti A. Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens 2005; 18:1282-7.
17. Nakayama M, Kawaguchi Y; Water and Electrolyte Balance (WEB) Study Group in CAPD. Multicenter survey on hydration status and control of blood pressure in Japanese CAPD patients. Perit Dial Int 2002; 22:411-14.
18. Takeda K, Nakamoto M, Hirakata H, Baba M, Kubo M, Fujishima M. Disadvantage of long-term CAPD for preserving cardiac performance: an echocardiographic study. Am J Kidney Dis 1998; 32:482-7.
19. Gunal AI, Ilkay E, Kirciman E, Karaca I, Dogukan A, Celiker H. Blood pressure control and left ventricular hypertrophy in long-term CAPD and hemodialysis patients: a cross-sectional study. Perit Dial Int 2003; 23:563-7.
20. Asci G, Ozkahya M, Duman S, Toz H, Erten S, Ok E. Volume control associated with better cardiac function in longterm peritoneal dialysis patients. Perit Dial Int 2006; 26: 85-8.
21. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69:1726-32.
22. Gunal AI, Kirciman E, Guler M, Yavuzkir M, Celiker H. Should the prevention of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren Fail 2004; 26:405-9.
23. Kooman JP, Cnossen N, Konings CJ, van der Sande FM, Leunissen KM. Is there a competition between urine volume and peritoneal ultrafiltration in peritoneal dialysis patients? Contrib Nephrol 2006; 150:111-18.
24. Schillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L, et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 2001; 19:2265-70.
25. Anan F, Yonemochi H, Masaki T, Takahashi N, Fukunaga N, Teshima Y, et al. High-density lipoprotein cholesterol and insulin resistance are independent and additive markers of left ventricular hypertrophy in essential hypertension. Hypertens Res 2007; 30:125-31.
26. Toikka JO, Ahotupa M, Viikari JS, Niinikoski H, Taskinen MR, Irjala K, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 1999; 147:133-8.
27. Perticone F, Maio R, Ceravolo R, Cosco C, Cloro C, Mattioli PL. Relationship between left ventricular mass and endothelium-dependent vasodilation in never-treated hypertensive patients. Circulation 1999; 99:1991-6.
28. van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998; 13:1782-6.
29. Yufu K, Takahashi N, Hara M, Saikawa T, Yoshimatsu H. Measurement of the brachial-ankle pulse wave velocity and flow-mediated dilatation in young, healthy smokers. Hypertens Res 2007; 30:607-12.
30. Nitta K, Akiba T, Uchida K, Otsubo S, Otsubo Y, Takei T, et al. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004; 27:47-52.
31. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111:2356-63.
32. Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 2006; 29:567-72.
33. Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 2000; 86:514-18.
34. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2004; 110: 1456-62.
35. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399-402.
36. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
37. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 Study): a randomized, double-blind trial. Lancet 2007; 370:153-60.
38. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis 2007; 50:791-802.